Hereditary angiodema: A current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema

Tom Bowen, Marco Cicardi, Konrad Bork, Bruce Zuraw, Mike Frank, Bruce Ritchie, Henriette Farkas, Lilian Varga, Lorenza C. Zingale, Karen Binkley, Eric Wagner, Peggy Adomaitis, Kristylea Brosz, Jeanne Burnham, Richard Warrington, Chrystyna Kalicinsky, Sean Mace, Christine McCusker, Robert Schellenberg, Lucia CelesteJacques Hebert, Karen Valentine, Man Chiu Poon, Bazir Serushago, Doris Neurath, William Yang, Gina Lacuesta, Andrew Issekutz, Azza Hamed, Palinder Kamra, John Dean, Amin Kanani, Donald Stark, Georges Etienne Rivard, Eric Leith, Ellie Tsai, Susan Waserman, Paul K. Keith, David Page, Silvia Marchesin, Hilary J. Longhurst, Wolfhart Kreuz, Eva Rusicke, Inmaculada Martinez-Saguer, Emel Aygören-Pürsün, George Harmat, George Füst, Henry Li, Laurence Bouillet, Teresa Caballero, Dumitru Moldovan, Peter J. Späth, Sara Smith-Foltz, Istvan Nagy, Erik W. Nielsen, Christoph Bucher, Patrik Nordenfeit, Yu Xiang Zhi

Research output: Contribution to journalArticlepeer-review

Abstract

Background: We published the Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) in 2004. Objective: To ensure that this consensus remains current. Methods: In collaboration with the Canadian Network of Rare Blood Disorder Organizations, we held the second Canadian Consensus discussion with our international colleagues in Toronto, Ontario, on February 3, 2006, and reviewed its content at the Fifth C1 Inhibitor Deficiency Workshop in Budapest on June 2, 2007. Papers were presented by international investigators, and this consensus algorithm approach resulted. Results: This consensus algorithm outlines the approach recommended for the diagnosis, therapy, and management of HAE, which was agreed on by the authors of this report. This document is only a consensus algorithm approach and continues to require validation. As such, participants agreed to make this a living 2007 algorithm, a work in progress, and to review its content at future international HAE meetings. Conclusions: There is a paucity of double-blind, placebo-controlled trials on the treatment of HAE, making levels of evidence to support the algorithm less than optimal. Controlled trials currently under way will provide further insight into the management of HAE. As with our Canadian 2003 Consensus, this 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of HAE was formed through the meeting and agreement of patient care professionals along with patient group representatives and individual patients.

Original languageEnglish (US)
Pages (from-to)S30-S40
JournalAnnals of Allergy, Asthma and Immunology
Volume100
Issue number1 SUPPL. 2
DOIs
StatePublished - Jan 2008
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Hereditary angiodema: A current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema'. Together they form a unique fingerprint.

Cite this